About 2 results found for searched term "Tusamitamab ravtansine" (0.128 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M25054 | Tusamitamab ravtansine | Drug-Linker Conjugates for ADC |
| SAR-408701; HuMAb2-3-SPDB-DM4 | ||
| Tusamitamab ravtansine (SAR-408701) is a DM4 anti-CEACAM5 antibody-drug conjugate (ADC). Tusamitamab ravtansine is composed of a humanized monoclonal antibody that binds carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) and a cytotoxic maytansinoid that selectively targets CEACAM5-expressing tumor cells. | ||
| M25086 | Tusamitamab | Others |
| Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
